Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 04 April 2012 | By Ansis Helmanis,
A public consultation on new criteria for prioritizing the review of drug approval applications is planned by Brazil's regulatory agency, ANVISA.
The agency intends to propose a point system for determining which drugs should be "placed in front of the queue for review."
According to the agency, an example of a marketing approval application that would get priority is for a generic version of a brand name drug that has no market competition.
ANVISA - Diretoria propõe novo critério para prioridades na fila de medicamentos
Tags: Queue, MAA, pharmaceutical, brazil, drug, review, submission
Regulatory Focus newsletters
All the biggest regulatory news and happenings.